MarketCap
Facebook
X
TelegramQuarterly report 2023-Q3
added 11-09-2023
Aravive Accounts Payables 2011-2026 | ARAV
Accounts payable — are the obligations of an organization to other legal entities or individuals that arise in cases when the company has acquired goods or services on deferred payment terms, has not paid taxes and fees, has wage arrears to employees, or has received loans and other liabilities. Accounts payable arise when an organization has already received some benefit but has not yet paid for it.Main types of accounts payable
| Type of liability | Example |
|---|---|
| To suppliers and contractors | Goods received but not yet paid for |
| Taxes and fees | VAT, income tax, etc., not paid on time |
| Salaries | Employee wages not paid |
| To budgets | Insurance contributions to funds not paid |
| To founders | Founders provided borrowed funds |
| To banks | Overdue loan payments |
| Other | Fines, penalties, forfeits, customer prepayments, etc. |
Impact on the company's financial performance
- Liquidity and solvency
Accounts payable are part of short-term liabilities, so they affect liquidity ratios - Financial stability
The higher the share of borrowed funds (including accounts payable), the lower the company's level of independence - Capital turnover
Moderate accounts payable can positively affect working capital by allowing the company to use “free” financing from suppliers (payment deferrals) - Risks and reputation
Large and especially overdue accounts payable may indicate financial difficulties. This can deter investors, partners, and lenders, and at a critical level of debt and lack of resources to repay it, bankruptcy proceedings may be initiated
Annual Accounts Payables Aravive
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 8.76 M | 2.66 M | 2.5 M | 1.08 M | 426 K | 1.5 M | 1.36 M | 1.67 M | 1.26 M | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 8.76 M | 426 K | 2.36 M |
Quarterly Accounts Payables Aravive
| 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 5.42 M | 3.89 M | 9.79 M | 8.76 M | 8.82 M | 4.7 M | 4.25 M | 2.66 M | 1.99 M | 3.6 M | 2.94 M | 2.5 M | 2.5 M | 2.5 M | 2.5 M | 1.08 M | 1.08 M | 1.08 M | 1.08 M | 426 K | 426 K | 426 K | 426 K | 1.5 M | 1.5 M | 1.5 M | 1.5 M | 1.36 M | 1.36 M | 1.36 M | 1.36 M | 1.67 M | 1.67 M | 1.67 M | 1.67 M | 1.26 M | 1.26 M | 1.26 M | 1.26 M | 315 K | 315 K | 315 K | 315 K | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 9.79 M | 315 K | 2.26 M |
Accounts Payables of other stocks in the Biotechnology industry
| Issuer | Accounts Payables | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Aptorum Group Limited
APM
|
3.24 M | $ 1.06 | -0.93 % | $ 5.78 M |  China |
 |
Autolus Therapeutics plc
AUTL
|
1.97 M | $ 1.82 | -4.85 % | $ 464 M |  Britain |
 |
Adagene
ADAG
|
4.24 M | $ 1.65 | - | $ 92.9 M | China |
 |
Arrowhead Pharmaceuticals
ARWR
|
17.7 M | $ 64.9 | -0.15 % | $ 8.68 B |  USA |
 |
AgeX Therapeutics
AGE
|
1.41 M | - | -10.17 % | $ 12.2 K | USA |
 |
Biogen
BIIB
|
424 M | $ 187.4 | 0.75 % | $ 27.3 B | USA |
 |
Akero Therapeutics
AKRO
|
9.03 M | - | - | $ 3.67 B | USA |
 |
Aeglea BioTherapeutics
AGLE
|
677 K | - | - | $ 1.01 B | USA |
 |
Albireo Pharma
ALBO
|
6.52 M | - | -0.23 % | $ 916 M | USA |
 |
Alpine Immune Sciences
ALPN
|
4.29 M | - | - | $ 2.17 B | USA |
 |
BioXcel Therapeutics
BTAI
|
16 M | $ 1.98 | -1.0 % | $ 5.02 M | USA |
 |
AlloVir
ALVR
|
247 K | - | 4.14 % | $ 49.1 M | USA |
 |
CASI Pharmaceuticals
CASI
|
4.79 M | $ 1.04 | -2.34 % | $ 142 M | USA |
 |
Ampio Pharmaceuticals
AMPE
|
750 K | - | -11.43 % | $ 502 K | USA |
 |
Catalyst Biosciences
CBIO
|
355 K | $ 10.74 | -2.1 % | $ 707 M | USA |
 |
Applied Molecular Transport
AMTI
|
1.58 M | - | - | $ 10.1 M | USA |
 |
Arena Pharmaceuticals
ARNA
|
13.3 M | - | -6.81 % | $ 3.04 B | USA |
 |
Athersys
ATHX
|
9.16 M | - | 3.77 % | $ 22.4 M | USA |
 |
Avenue Therapeutics
ATXI
|
155 K | - | -52.27 % | $ 4.45 M | USA |
 |
Celldex Therapeutics
CLDX
|
3.26 M | $ 27.0 | -1.28 % | $ 1.74 M | USA |
 |
BioVie
BIVI
|
2.2 M | $ 1.27 | -2.31 % | $ 1.88 M | USA |
 |
ARCA biopharma
ABIO
|
3.46 M | - | 1052.0 % | $ 415 M | USA |
 |
Acasti Pharma
ACST
|
601 K | - | 4.01 % | $ 150 M |  Canada |
 |
Adaptimmune Therapeutics plc
ADAP
|
8.13 M | - | -15.15 % | $ 60.3 M | Britain |
 |
AVROBIO
AVRO
|
27 K | - | 1083.1 % | $ 745 M | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
30.5 M | $ 27.75 | 0.02 % | $ 1.34 B | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
561 K | $ 4.14 | -3.72 % | $ 9.01 B |  Israel |
 |
Acer Therapeutics
ACER
|
3.81 M | - | 2.71 % | $ 14 M | USA |
 |
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
51.7 M | $ 11.13 | -2.02 % | $ 720 M | USA |
 |
BioDelivery Sciences International
BDSI
|
8.11 M | - | -4.8 % | $ 255 M | USA |
 |
Axon Enterprise
AXON
|
72 M | $ 633.45 | 3.34 % | $ 48 B | USA |
 |
Ayala Pharmaceuticals
AYLA
|
4.08 M | - | - | $ 7.46 M | Israel |
 |
Aytu BioScience
AYTU
|
10.6 M | $ 2.64 | -0.75 % | $ 16.6 M | USA |
 |
BeiGene, Ltd.
BGNE
|
405 M | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Bellicum Pharmaceuticals
BLCM
|
486 K | - | -9.72 % | $ 5.89 M | USA |